Cáceres Méndez Edward Andres
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cáceres Méndez Edward Andres has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Mariño Correa
Departamento de Medicina Interna Pontificia Universidad Javeriana Bogotá Colombia
3 shared publications - Cristian Orlando Porras Bueno
Pontificia Universidad Javeriana
2 shared publications - Ángel Alberto García Peña
Department of Internal Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia
2 shared publications - Carlos Hernán Calderón Franco
Hospital Santa Clara, Bogotá Colombia
1 shared publication - Carolina Murgueitio Guzmán
Department of Internal Medicine Pontificia Universidad Javeriana Bogota Colombia
1 shared publication - Cándida Diaz-Brochero
Pontificia Universidad Javeriana
1 shared publication
Latest Publications
- Open Access
- 31 August 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (9)
When Myocardial Injury in Lupus Is Not Lupus: Probable Antimalarial‐Associated Cardiomyopathy Mimicking Lupus Myocarditis
Antimalarial cardiotoxicity may mimic lupus myocarditis in systemic lupus erythematosus. We report a 53‐year‐old woman with chronic antimalarial exposure, myocardial injury, biventricular dysfunction, electrical abnormalities, low lupus activity, and no myocardial edema. Chloroquine withdrawal was followed by clinical improvement and left ventricular function recovery, supporting probable antimalarial‐associated cardiomyopathy.
- 31 August 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (9)
Open AccessWhen Myocardial Injury in Lupus Is Not Lupus: Probable Antimalarial‐Associated Cardiomyopathy Mimicking Lupus Myocarditis
Antimalarial cardiotoxicity may mimic lupus myocarditis in systemic lupus erythematosus. We report a 53‐year‐old woman with chronic antimalarial exposure, myocardial injury, biventricular dysfunction, electrical abnormalities, low lupus activity, and no myocardial edema. Chloroquine withdrawal was followed by clinical improvement and left ventricular function recovery, supporting probable antimalarial‐associated cardiomyopathy.
- Open Access
- 9 July 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (7) , e72769
Utility of the Triglyceride and HDL Cholesterol Index in Older Persons in Colombia
Background: Alterations in lipid metabolism are key contributors to the development of atherogenesis and the increasing prevalence of atherosclerotic cardiovascular diseases, including coronary artery disease, peripheral arterial disease, and cerebrovascular disease. The triglyceride‐to‐HDL cholesterol (TG/HDL‐c) index is commonly used to assess cardiovascular disease risk; however, its effectiveness in older adults remains unclear. Methods: This study evaluated the association and predictive capacity of the TG/HDL‐c index for cardiometabolic risk factors in older adults from the SABE Colombian study. A cross‐sectional analysis was performed among adults aged ≥ 60 years from the national SABE survey. Univariable and multivariable logistic regression models were constructed to examine associations between the TG/HDL‐c index and diabetes or metabolic syndrome, adjusting for age, sex, BMI, smoking, diet, and physical activity. Discriminatory capacity was assessed using receiver operating characteristic curves, and optimal cut‐off points were determined using the Youden index. Results: A total of 23,694 participants with a median age of 69 years were included; 57.3% were women. The TG/HDL‐c index was independently associated with both diabetes (adjusted OR per 1 SD: 1.25; 95% CI: 1.13–1.37; p < 0.001) and metabolic syndrome (adjusted OR per 1 SD: 2.82; 95% CI: 2.46–3.22; p < 0.001). The index demonstrated a good discriminatory performance for diabetes (AUC = 0.89; 95% CI: 0.86–0.93; cut‐off = 9.17; sensitivity = 0.81; specificity = 0.90) and metabolic syndrome (AUC = 0.86; 95% CI: 0.85–0.88; cut‐off = 8.81; sensitivity = 0.71; specificity = 0.92). In contrast, discriminatory performance was limited for hypertension, prediabetes, cardiovascular disease, and cerebrovascular disease (AUC range 0.52–0.67). Conclusions: The TG/HDL‐c index was independently associated with diabetes and metabolic syndrome and demonstrated good discriminatory performance in this nationally representative sample of older adults. Although these results highlight its potential utility for identifying individuals at higher cardiometabolic risk, further longitudinal studies are needed to validate these findings and determine the prognostic value of TG/HDL‐c for clinical decision‐making in elderly populations.
- 9 July 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (7) , e72769
Open AccessUtility of the Triglyceride and HDL Cholesterol Index in Older Persons in Colombia
Background: Alterations in lipid metabolism are key contributors to the development of atherogenesis and the increasing prevalence of atherosclerotic cardiovascular diseases, including coronary artery disease, peripheral arterial disease, and cerebrovascular disease. The triglyceride‐to‐HDL cholesterol (TG/HDL‐c) index is commonly used to assess cardiovascular disease risk; however, its effectiveness in older adults remains unclear. Methods: This study evaluated the association and predictive capacity of the TG/HDL‐c index for cardiometabolic risk factors in older adults from the SABE Colombian study. A cross‐sectional analysis was performed among adults aged ≥ 60 years from the national SABE survey. Univariable and multivariable logistic regression models were constructed to examine associations between the TG/HDL‐c index and diabetes or metabolic syndrome, adjusting for age, sex, BMI, smoking, diet, and physical activity. Discriminatory capacity was assessed using receiver operating characteristic curves, and optimal cut‐off points were determined using the Youden index. Results: A total of 23,694 participants with a median age of 69 years were included; 57.3% were women. The TG/HDL‐c index was independently associated with both diabetes (adjusted OR per 1 SD: 1.25; 95% CI: 1.13–1.37; p < 0.001) and metabolic syndrome (adjusted OR per 1 SD: 2.82; 95% CI: 2.46–3.22; p < 0.001). The index demonstrated a good discriminatory performance for diabetes (AUC = 0.89; 95% CI: 0.86–0.93; cut‐off = 9.17; sensitivity = 0.81; specificity = 0.90) and metabolic syndrome (AUC = 0.86; 95% CI: 0.85–0.88; cut‐off = 8.81; sensitivity = 0.71; specificity = 0.92). In contrast, discriminatory performance was limited for hypertension, prediabetes, cardiovascular disease, and cerebrovascular disease (AUC range 0.52–0.67). Conclusions: The TG/HDL‐c index was independently associated with diabetes and metabolic syndrome and demonstrated good discriminatory performance in this nationally representative sample of older adults. Although these results highlight its potential utility for identifying individuals at higher cardiometabolic risk, further longitudinal studies are needed to validate these findings and determine the prognostic value of TG/HDL‐c for clinical decision‐making in elderly populations.
- 16 March 2026
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 81 (3) , 374-385
Performance of the LEVO-D score in patients with advanced heart failure at a referral hospital
Advanced heart failure is a prevalent and burdensome condition, and effective therapies are needed. Ambulatory intermittent levosimendan infusion has been used to reduce cardiovascular events, although response rates vary. This study assessed the LEVO-D score as a predictive tool in patients receiving levosimendan infusions under standardised conditions. We conducted a prospective observational study at the Heart Failure Clinic of a tertiary-level teaching hospital between September 2020 and March 2024. A total of 67 patients received a median of 10 intermittent levosimendan infusions and were followed for a mean duration of 18 months. The performance of the LEVO-D score was assessed using receiver operating characteristic (ROC) curve analysis and descriptive statistics. The patients were elderly, with a mean age of 69.5 years, a high comorbidity burden, and an advanced functional class. All patients received beta-blockers, and most had a high rate of guideline-directed therapy. At 18 months, the mortality rate was 36.2% and the hospitalisation rate was 42%. The LEVO-D score showed good predictive value for hospitalisation (AUC 0.81), moderate predictive value for clinical response (AUC 0.64), and poor predictive value for mortality (AUC 0.58). A cut-off value of ≥1.0 provided the optimal balance between sensitivity and specificity for identifying responders. The LEVO-D score showed consistent discriminatory capacity in our cohort despite a high rate of optimal medical therapy and a low rate of edge-to-edge transcatheter repair, thus supporting its utility and encouraging further validation in diverse clinical settings.
- 16 March 2026
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 81 (3) , 374-385
Performance of the LEVO-D score in patients with advanced heart failure at a referral hospital
Advanced heart failure is a prevalent and burdensome condition, and effective therapies are needed. Ambulatory intermittent levosimendan infusion has been used to reduce cardiovascular events, although response rates vary. This study assessed the LEVO-D score as a predictive tool in patients receiving levosimendan infusions under standardised conditions. We conducted a prospective observational study at the Heart Failure Clinic of a tertiary-level teaching hospital between September 2020 and March 2024. A total of 67 patients received a median of 10 intermittent levosimendan infusions and were followed for a mean duration of 18 months. The performance of the LEVO-D score was assessed using receiver operating characteristic (ROC) curve analysis and descriptive statistics. The patients were elderly, with a mean age of 69.5 years, a high comorbidity burden, and an advanced functional class. All patients received beta-blockers, and most had a high rate of guideline-directed therapy. At 18 months, the mortality rate was 36.2% and the hospitalisation rate was 42%. The LEVO-D score showed good predictive value for hospitalisation (AUC 0.81), moderate predictive value for clinical response (AUC 0.64), and poor predictive value for mortality (AUC 0.58). A cut-off value of ≥1.0 provided the optimal balance between sensitivity and specificity for identifying responders. The LEVO-D score showed consistent discriminatory capacity in our cohort despite a high rate of optimal medical therapy and a low rate of edge-to-edge transcatheter repair, thus supporting its utility and encouraging further validation in diverse clinical settings.
- Open Access
- 4 March 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (3) , e70213
An Unusual Case of 11αB ‐Crystallin ( CRYAB ) Mutation as a Cause of Dilated Cardiomyopathy With Restrictive Physiology: A Case Report and Focused Review of the Literature
Several diseases have been linked to αB‐crystallin (CRYAB) mutation. However, this mutation is an uncommon cause that has been associated in recent years with the development of dilated cardiomyopathy. We report a case of dilated cardiomyopathy with restrictive physiology due to a CRYAB mutation.
- 4 March 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (3) , e70213
Open AccessAn Unusual Case of 11αB ‐Crystallin ( CRYAB ) Mutation as a Cause of Dilated Cardiomyopathy With Restrictive Physiology: A Case Report and Focused Review of the Literature
Several diseases have been linked to αB‐crystallin (CRYAB) mutation. However, this mutation is an uncommon cause that has been associated in recent years with the development of dilated cardiomyopathy. We report a case of dilated cardiomyopathy with restrictive physiology due to a CRYAB mutation.